Literature DB >> 8780056

Dopamine D3 (auto) receptors inhibit dopamine release in the frontal cortex of freely moving rats in vivo.

A Gobert1, F Lejeune, J M Rivet, L Cistarelli, M J Millan.   

Abstract

In freely moving rats, the novel, selective dopamine (DA) D3 receptor agonist PD 128,907 dose-dependently [effective dose (ED25) = 0.07 mg/kg, s.c.] reduced dialysate levels of DA in the frontal cortex, a structure innervated by the ventral tegmental area (VTA). This action of PD 128,907 (0.16 mg/kg, s.c.) was abolished by a selective DA D3 receptor antagonist S 14297 (1.25 mg/kg, s.c.), which alone did not modify levels of DA. In contrast to S 14297, its inactive distomer, S 17777, did not modify the actions of PD 128,907. In addition, PD 128,907 dose-dependently and potently inhibited the firing rate of VTA-localized neurons in anesthetized rats (ED50 = 0.001 mg/kg, i.v.). S 14297, but not S 17777, completely reversed the actions of PD 128,907 (0.005 mg/kg, i.v.) with a 50% inhibitory dose of 0.03 mg/kg, i.v. and did not itself significantly modify the firing rate. In conclusion, these data provide the first direct evidence that DA D3 (auto) receptors modulate (inhibit) the release of DA in the frontal cortex.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8780056     DOI: 10.1046/j.1471-4159.1996.66052209.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  13 in total

1.  Activation of human D3 dopamine receptor inhibits P/Q-type calcium channels and secretory activity in AtT-20 cells.

Authors:  E V Kuzhikandathil; G S Oxford
Journal:  J Neurosci       Date:  1999-03-01       Impact factor: 6.167

Review 2.  Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice.

Authors:  T E Koeltzow; M Xu; D C Cooper; X T Hu; S Tonegawa; M E Wolf; F J White
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

Review 3.  The potential role of dopamine D₃ receptor neurotransmission in cognition.

Authors:  Shinichiro Nakajima; Philip Gerretsen; Hiroyoshi Takeuchi; Fernando Caravaggio; Tiffany Chow; Bernard Le Foll; Benoit Mulsant; Bruce Pollock; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2013-06-20       Impact factor: 4.600

4.  Disruption of prepulse inhibition of the startle reflex by the preferential D(3) agonist ropinirole in healthy males.

Authors:  Stella G Giakoumaki; Panos Roussos; Sophia Frangou; Panos Bitsios
Journal:  Psychopharmacology (Berl)       Date:  2007-06-20       Impact factor: 4.530

5.  Dopamine D3 Receptor Availability Is Associated with Inflexible Decision Making.

Authors:  Stephanie M Groman; Nathaniel J Smith; J Ryan Petrullli; Bart Massi; Lihui Chen; Jim Ropchan; Yiyun Huang; Daeyeol Lee; Evan D Morris; Jane R Taylor
Journal:  J Neurosci       Date:  2016-06-22       Impact factor: 6.167

Review 6.  Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.

Authors:  Gerhard Gross; Karsten Wicke; Karla U Drescher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-11-06       Impact factor: 3.000

7.  Midbrain D3 Receptor Availability Predicts Escalation in Cocaine Self-administration.

Authors:  Stephanie M Groman; Ansel T Hillmer; Heather Liu; Krista Fowles; Daniel Holden; Evan D Morris; Daeyeol Lee; Jane R Taylor
Journal:  Biol Psychiatry       Date:  2020-02-27       Impact factor: 13.382

8.  Dominant-negative mutants identify a role for GIRK channels in D3 dopamine receptor-mediated regulation of spontaneous secretory activity.

Authors:  E V Kuzhikandathil; G S Oxford
Journal:  J Gen Physiol       Date:  2000-06       Impact factor: 4.086

9.  Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients.

Authors:  Angela Deutschländer; Christian la Fougère; Kai Boetzel; Nathalie L Albert; Franz-Josef Gildehaus; Peter Bartenstein; Guoming Xiong; Paul Cumming
Journal:  Neuroimage Clin       Date:  2016-06-09       Impact factor: 4.881

10.  The novel atypical antipsychotic cariprazine demonstrates dopamine D2 receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activity.

Authors:  Sarah Delcourte; Charles R Ashby; Renaud Rovera; Béla Kiss; Nika Adham; Bence Farkas; Nasser Haddjeri
Journal:  CNS Neurosci Ther       Date:  2018-05-04       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.